$BBIO News

Last published 16h ago

16h agoBBIOBridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026GlobeNewswirePALO ALTO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced 28 abstracts on acoramidis in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) comprised of 12 new posters, seven encore poster presenta ...
2d agoBBIOBridgeBio to Participate in November and December Investor ConferencesGlobeNewswirePALO ALTO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:
2d agoBBIOBridgeBio to Participate in November and December Investor ConferencesGlobeNewswirePALO ALTO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on
5d agoBBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePALO ALTO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company...
5d agoBBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePALO ALTO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic
1w agoBBIOBridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026GlobeNewswirePALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on
1w agoBBIOBridgeBio Q3 2026 Earnings Call - BRIDGEBIO PHARMA INCEarnings Call TranscriptsHello, everyone. Thank you for joining us, and welcome to BridgeBio Third Quarter 2026 Earnings Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, pleas
1w agoBBIOBridgeBio Pharma, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoBBIOBridgeBio Reports Third Quarter 2026 Financial Results and Corporate UpdatesGlobeNewswire- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over year). Loss from
2w agoBBIOBridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ETGlobeNewswirePALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic
3w agoBBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic
1mo agoBBIOAcoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health RecordsGlobeNewswire- In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a statistically
1mo agoBBIOEncaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1GlobeNewswire- Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1 - 100% of participants who received encaleret reported improvements in at least one ADH1
1mo agoBBIOBridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual MeetingGlobeNewswirePALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on
1mo agoBBIOBridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026GlobeNewswirePALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on
1mo agoBBIOBridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis DayPR NewswireBridgeBio Pharma, Inc. (Nasdaq: BBIO) (the "Company" or "BridgeBio"), a commercial-stage, multi-product biopharmaceutical company focused on genetic...
1mo agoBBIOBERNSTEIN INSIGHTS HEALTHCARE LEADERS AND DISRUPTORS - 3RD ANNUAL HEALTHCARE FORUM - BRIDGEBIO PHARMA INCEarnings Call TranscriptsWell, thank you so much, everybody. Thank you for joining us, Thomas and Julie, from BridgeBio. It's really nice to have you here. And we'll kick it off first with you guys presenting some slides and giving an overview b
1mo agoBBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic
1mo agoBBIOMorgan Stanley 24th Annual Global Healthcare Conference - BRIDGEBIO PHARMA INCEarnings Call TranscriptsGood morning everyone. I'm Sean Lyman, Head of US Mid-Cap Biotech Equity Research here at Morgan Stanley and welcome to the Morgan Stanley Global Healthcare Conference. Before we commence I'll make you aware of some impo
2mo agoBBIOWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - BRIDGEBIO PHARMA INCEarnings Call Transcriptsgood afternoon everyone thanks for joining us uh here after the one session get right back into the the fireside discussions so my name is derek archula i'm one of the biotech analysts here at wells fargo uh really excit
2mo agoBBIOOral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 TrialGlobeNewswire- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events Stabilization of
2mo agoBBIOBridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026GlobeNewswirePALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on
2mo agoBBIOBridgeBio to Participate in September Investor ConferencesGlobeNewswirePALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on
2mo agoBBIOBridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for AmericansGlobeNewswire- This voluntary agreement expands access for Medicaid patients to BridgeBio’s currently marketed medicine and lowers drug costs for Americans without jeopardizing innovation and sustainability in rare diseases -
2mo agoBBIOAcoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CMGlobeNewswire- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showing clinically
2mo agoBBIOBridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026GlobeNewswirePALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic
2mo agoBBIOBridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder BaseGlobeNewswire- The transaction supports the evolution of the Company’s shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO)
3mo agoBBIOBridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing ShareholderGlobeNewswirePALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic
3mo agoBBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic
3mo agoBBIOBridgeBio Q2 2026 Earnings Call - BRIDGEBIO PHARMA INCEarnings Call TranscriptsGood afternoon. I will be your conference operator today. All lines have been placed on mute to prevent any background noise. After the company's remarks, there will be a question and answer session. If you would like to
3mo agoBBIOBridgeBio Reports Second Quarter 2026 Financial Results and Corporate UpdatesGlobeNewswire- $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep
3mo agoBBIOBridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ETGlobeNewswirePALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic
3mo agoBBIOBridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1GlobeNewswire- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbuster opportunity
4mo agoBBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic
4mo agoBBIOAcoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CMGlobeNewswire- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P<0.05), with no
4mo agoBBIO KKRBridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming LaunchesGlobeNewswire- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company’s
4mo agoBBIOBridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with AchondroplasiaGlobeNewswire- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant
4mo agoBBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePALO ALTO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic
4mo agoNTHI LLY BIIB BBIOInternational Regulatory Pathways Have Supported Drug Development Across Biotech and PharmaGlobeNewswireDENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights
4mo agoBBIOBridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026GlobeNewswirePALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on
5mo agoBBIOGoldman Sachs 47th Annual Global Healthcare Conference - BRIDGEBIO PHARMA INCEarnings Call TranscriptsOkay, good morning, and thank you for joining us on day two of the 47th annual Goldman Sachs Global Healthcare Conference. I'm Paul Choi, and I cover the SMIDCAP biotech sector here at the firm. It's my pleasure to host
5mo agoBBIOJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - BRIDGEBIO PHARMA INCEarnings Call TranscriptsWe're going to get started with our next session. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thanks for joining me today. And it's my pleasure to have the BridgeBio team with me. To my direct left is Tom Trema
5mo agoBBIOBridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9GlobeNewswire- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for
6mo agoBBIO2026 GLOBAL HEALTHCARE CONFERENCEBRIDGEBIO PHARMA INCEarnings Call TranscriptsWelcome to the afternoon session on this, our first day at the Annual Healthcare Conference in Toste, Las Vegas. My name is Jason Zemanski. I'm one of the SMITCAP analysts here at B of A. Very pleased to have joined me,
6mo agoBBIO BMY ARWR AMGNWall Street's Cardiac Bet: Where Diagnostics Meet the MoneyPR NewswireCardiovascular disease is about to become the most expensive problem in American medicine. The American Heart Association fired a warning shot in...
6mo agoBBIOBridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1GlobeNewswire- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-specified primary
6mo agoBBIOAcoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart FailureGlobeNewswire-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated profile in ATTR-CM
6mo agoBBIOBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today
6mo agoBBIOBridgeBio Q1 2026 Earnings CallBRIDGEBIO PHARMA INCEarnings Call TranscriptsGood afternoon. I will be your conference operator today. All lines have been placed and muted to prevent any background noise. After the company's remarks, there will be a question and answer session. If you would like
6mo agoBBIOBridgeBio Reports First Quarter 2026 Financial Results and Corporate UpdatesGlobeNewswire$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentumContinued